June 27, 2017
Strongbridge Biopharma plc Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome
Media
June 27, 2017
Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA
June 26, 2017
Strongbridge Biopharma plc Added to the Russell 3000® Index
June 21, 2017
Final price in BONESUPPORT™’s initial public offering set at SEK 29 per share – trading on Nasdaq Stockholm commences today
June 20, 2017
Onxeo successfully raises €15 Million with US and European investors
June 19, 2017
Nordic Nanovector to present to investors at the Citi European Healthcare Conference
June 19, 2017
Onxeo launches a capital increase by means of an accelerated book-build offering
June 14, 2017
Tisbury Pharmaceuticals Launches with a USD 32 Million Series A Financing to Develop First-in-class Therapeutics for Glaucoma
June 14, 2017
Single dose Betalutin® continues to show promising efficacy and safety in recurrent indolent NHL patients
June 14, 2017
GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)